Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Spurdle AB, Deans AJ, Duffy D, Goldgar DE, Chen X, Beesley J; kConFaB; Easton DF, Antoniou AC, Peock S, Cook M; EMBRACE Study Collaborators; Nathanson KL, Domchek SM, MacArthur GA, Chenevix-Trench G. Spurdle AB, et al. Breast Cancer Res Treat. 2009 May;115(2):307-13. doi: 10.1007/s10549-008-0083-5. Epub 2008 Jun 10. Breast Cancer Res Treat. 2009. PMID: 18543099
Breast cancer susceptibility variants alter risks in familial disease.
Latif A, Hadfield KD, Roberts SA, Shenton A, Lalloo F, Black GC, Howell A, Evans DG, Newman WG. Latif A, et al. Among authors: evans dg. J Med Genet. 2010 Feb;47(2):126-31. doi: 10.1136/jmg.2009.067256. Epub 2009 Jul 16. J Med Genet. 2010. PMID: 19617217
Update on genetic predisposition to breast cancer.
Ahmed M, Lalloo F, Evans DG. Ahmed M, et al. Among authors: evans dg. Expert Rev Anticancer Ther. 2009 Aug;9(8):1103-13. doi: 10.1586/era.09.38. Expert Rev Anticancer Ther. 2009. PMID: 19671030 Review.
Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Spurdle AB, Fahey P, Chen X, McGuffog L; kConFab; Easton D, Peock S, Cook M; EMBRACE; Simard J; INHERIT; Rebbeck TR; MAGIC; Antoniou AC, Chenevix-Trench G. Spurdle AB, et al. Breast Cancer Res Treat. 2010 Jul;122(1):281-5. doi: 10.1007/s10549-009-0601-0. Epub 2009 Nov 18. Breast Cancer Res Treat. 2010. PMID: 19921428 Free PMC article.
Isolated unilateral vestibular schwannomas do not harbor HRAS mutations.
Smith MJ, Hadfield KD, Ramsden RT, Rutherford SA, King AT, Newman WG, Evans DG. Smith MJ, et al. Among authors: evans dg. Am J Med Genet A. 2010 Jun;152A(6):1586-7. doi: 10.1002/ajmg.a.33409. Am J Med Genet A. 2010. PMID: 20503341 No abstract available.
Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy.
Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, Purdie CA, Jordan LB, Ferraldeschi R, Latif A, Hadfield KD, Clarke RB, Ashcroft L, Evans DG, Howell A, Nikoloff M, Lawrence J, Newman WG. Thompson AM, et al. Among authors: evans dg. Breast Cancer Res Treat. 2011 Jan;125(1):279-87. doi: 10.1007/s10549-010-1139-x. Epub 2010 Sep 1. Breast Cancer Res Treat. 2011. PMID: 20809362
1,326 results